Fig. 6

Association between the CDI signature and different likelihoods of immunotherapeutic response. (A) Comparison of the expression of immune checkpoint molecules, namely PD-1, PD-L1, and CTLA4 between high- and low-risk groups of CDI signature. (B) Comparison of the percentage of the responders to immunotherapy between high- and low-risk groups of CDI. TIDE algorithm was used to predict the likelihood of immunotherapeutic response. (C) Comparison of the likelihood of the response to immunotherapy between high- and low-risk groups of CDI. Submap analysis was used to predict the likelihood of immunotherapeutic response. R, response.